NP-C Therapeutics Overview
- Founded
- 2014
- Status
- Out of Business
- Latest Deal Type
- Out of Business
NP-C Therapeutics General Information
Description
Developer of a treatment therapy designed to treat Niemann-Pick Type C. The company's treatment therapy uses combination of three drugs which help to treat lysosomal storage diseases, enabling patients to recover severe liver disease from infiltration of the liver and respiratory failure from infiltration of the lungs.
Contact Information
Website
Ownership Status
Out of Business
Financing Status
Formerly Angel backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
- 650 Park Avenue
- Suite 20
- King of Prussia, PA 19406
- United States
NP-C Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Out of Business | 01-Jun-2017 | 00000 | Completed | Out of Business | ||
| 1. Angel (individual) | 01-Apr-2016 | 00000 | 00000 | Completed | Startup |
NP-C Therapeutics Executive Team (3)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Kasturi Haldar Ph.D | Chief Scientific Officer | ||
| William Claypool MD | President, Board Member & Chief Executive Officer | ||
| Dennis Willson | Chairman |
NP-C Therapeutics Board Members (1)
| Name | Representing | Role | Since |
|---|---|---|---|
| Dennis Willson | Self | Chairman | 000 0000 |